NANOBIOTIX TO PARTICIPATE IN FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE Paris, France; Cambridge, Massachusetts (USA)

NANOBIOTIX TO PARTICIPATE IN FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE

Paris, France; Cambridge, Massachusetts (USA); May 26, 2021 - NANOBIOTIX

(Euronext : NANO -- NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today

announced that Laurent Levy, co-founder and chief executive officer, will discuss the Company's latest corporate and clinical developments in a fireside chat at the Jefferies Virtual Healthcare Conference on

the 4th of June at 8:00 AM Eastern Time (14:00 Central European Time).

A live webcast of the discussion, as well as an archived recording may be accessed by visiting the events section of

the Company's website.

Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients;

supported by people committed to making a difference for humanity. The company's philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.

Incorporated in 2003, Nanobiotix is headquartered in Paris, France, and has subsidiaries in Cambridge, Massachusetts (United States) as well as France, Spain, and Germany.

Nanobiotix has been listed on Euronext: Paris since 2012 and on the Nasdaq Global Select Market in New York City in December 2020.

Nanobiotix is the owner of more than 30 umbrella patents associated with three (3) nanotechnology platforms with applications in 1) oncology; 2) bioavailability and

biodistribution; and 3) disorders of the central nervous system. The Company's resources are primarily devoted to the development of its lead product candidate-NBTXR3-which is th eproduct of its proprietary oncology platform and has already

achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under the brand name Hensify .